Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Webcasts|January 16, 2025

Quantifying Host Cell Proteins by LC-MS: Experimental Demonstration and Method Comparison in USP 1132.1

Author(s)USP

Webinar Date/Time: Wed, Feb 26, 2025 11:00 AM EST

Register Free: https://www.biopharminternational.com/bp_w/experimental-demonstration

Event Overview:

The demand for orthogonal methods providing detailed information on individual HCPs has increased. This has culminated in the establishment of the new USP-NF Chapter 〈1132.1〉 Residual Host Cell Protein Measurement in Biopharmaceuticals by Liquid Chromatography-Mass Spectrometry, which outlines 3 methods for quantifying HCPs using mass spectrometry (MS). HCP analysis by MS is complex, expensive, and necessitates skilled professionals for setup and operation, and its implementation can pose significant challenges. This raises the question: how can these methods be integrated into practical testing, and what are the advantages, disadvantages, and potential pitfalls of each method?


Key Learning Objectives:

  • Understand the 3 quantitative methods that can be used to assess HCPs in a biotherapeutics:
    a)relative to the product protein,
    b) relative to spiked-in proteins, and
    c) relative to the spiked-in peptides.
  • Learn the benefits of each method.


Who Should Attend:
Director, Manager, Head of, Scientist of:

  • mAb development or manufacturing
  • CMC analytical method development
  • Process analytics (biologics)
  • Quality control / assurance / testing
  • Protein sciences
  • Translational research scientist
  • Mass spectrometrists

Speakers:

Derrick Zhang, MSc
Senior Scientist II
USP

Derrick Zhang, MSc, is a senior scientist II at US Pharmacopeia, leading the development of reference standards and analytical reference material for biologics. In his previous roles at Adaptive Phage Therapeutics, he oversaw the analytical development and qualification of potency and characterization assays, including LC/MS and ELISA for host cell protein analysis for drug substance (DS) release. At United Therapeutics Corporation, he managed assay development for DS characterization, including validation of process-specific HCP-ELISA for GMP release testing.

Victor Chrone, MSc
Bioinformatics Scientist
Alphalyse

Victor Guldmann Chrone is a bioinformatics and protein scientist at Alphalyse. He holds a master’s degree in computational biomedicine from the University of Southern Denmark, where he focused on the structural characterization of monoclonal antibodies using cross-linking liquid chromatography–tandem mass spectrometry (LC-MS). Chrone’s research concentrates on bioinformatics on host cell protein and quality control when utilizing LC-MS. He has extensive experience in LC-MS-based proteomics, data mining, machine learning, and data visualization.

Register Free: https://www.biopharminternational.com/bp_w/experimental-demonstration


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.